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Abstract
The high genetic compatibility between the 2009 H1N1 pandemic "swine flu" and
the highly pathogenic H5N1 "bird flu" viruses indicates that the odds of a deadly bird flu
strain mingling its genetic material with a human virus and becoming easily
transmissible among humans are at an all-time high. This fact stresses the urgent need
for new treatment and prevention methods to combat influenza. Our current antiinfluenza

weapons

include

vaccination

and

two

type

of

antivirals

that

target specific viral components (the so-called M2 ion channel inhibitors and the
neuraminidase inhibitors). However, the high genetic variability of the virus enables it to
easily circumvent by favoring the development of mutations that either, change the
antigenic makeup of the virus making it unrecognizable by the immune effectors
stimulated by vaccination, or confer resistance against the antivirals indicated above. A
promising new alternative for the development of broad-spectrum antivirals is to develop
small molecules capable of either, decreasing the activity or abundance of cellular
components essential for viral replication, or increasing the activity or abundance of
cellular components endowed with antiviral activity. In this project we aim to further
characterize the role played by the so-called cellular SUMOylation system during
influenza virus infections, to determine whether it may provide new targets for the
development of innovative anti-influenza therapies. Specifically, my work focuses on
delineating the molecular effects mediated by the SUMOylation of the viral protein NEP,
an essential viral factor required for the export of viral components from the cell
nucleus.
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Chapter 1: Introduction
Influenza is an acute contagious respiratory disease characterized by recurrent
annual epidemics with occasional but major worldwide pandemics. Despite all the
efforts and current available anti-influenza therapies, it continues to represent a major
threat to global human health. Influenza continues to cause severe illness to 3-5 million
people and 250,000- 500,000 annual deaths worldwide, where 20,000-36,000 deaths
account for the United States alone each year during epidemic seasons [1]. The
seasonal influenza virus affects people from all ages, particularly the elderly from age
65 and older. The 2009 H1N1 influenza pandemic included a new high risk population
by affecting younger children. People with certain health problems such as chronic
heart, pulmonary diseases, liver and kidney damage, and metabolic diseases such as
diabetes are at a higher risk of death due to the weakening of the body’s ability to fight
off the disease [1]. Society has experienced three major influenza pandemics worldwide
during the last century, in 1918, 1957, 1968, and 2009. The 1918 Spanish flu pandemic
killed 50 to100 million people worldwide, 28% of the total population at the time, making
it one of the deadliest natural disasters in human history [2].
The most effective way to combat influenza is through vaccination. Currently,
there are a few known anti-viral drugs against influenza, which target structural
components of the virus; M2 and NA. Unfortunately, only one of them is effective since
the M2 inhibitor, best known as amantadine, has shown resistance on 100% of
seasonal H3N2 and 2009 H1N1viruses [3].This is possible due to the low fidelity of the
viral polymerase which renders the virus prone to mutations and to develop resistance
against available antiviral therapies. Recent findings in 2010 indicated the high genetic
1

compatibility between swine-origin H1N1 and the highly pathogenic avian H5N1
influenza viruses [4].Reassortment of the viruses containing HA from H5N1 and other
genes from the 2009 H1N1 virus are better at replicating in human lung cells than any of
the viruses alone, thus creating a dangerously improved human influenza strain. Even
more recently in February 2013, the appearance of a new H7N9 influenza strain was
reported in China with an on-going spread through Asia. According to reports from the
World Health Organization, WHO, the new strain has infected 133 people in China and
Taiwan, killing 43 of them. Even though, there have not been any cases reported in the
United States yet, there is an urgent need for novel therapeutic and prophylactic
methods to combat the disease. A viable alternative for the development of novel broadspectrum tools against influenza virus is to target cellular components required for viral
multiplication that will work irrespectively of the type, strain or antigen properties of the
virus.
The Small Ubiquitin-like MOdifier, SUMO, is among the most dynamic posttranslational regulation systems composed by four isoforms in humans (SUMO1-4).
These proteins are conjugated to lysine residue(s) in their target protein by a common
enzymatic pathway in a process known as SUMOylation, exerting hundreds of effects
on cellular proteins and regulating numerous cellular activities. Many reports have
shown crucial roles for SUMOylation in the life cycle of several viruses [5]. Moreover,
previous data by our group indicated that influenza virus affects and is affected by the
cellular SUMOylation system of the host [6], suggesting a critical role for the cellular
SUMOylation system during influenza virus infection. Therefore, this post-translational
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SUMOylation system

may

important targets for

the development of

innovative

therapies.

antiviral

The influenza

provide

viral segment 8 is an

essential fragment coding a 121 amino acid polypeptide from a spliced form of the
segment mRNA transcript. This not well characterized, and the second smallest
influenza viral protein was originally thought to have no structural function within the
virion, leading to its designation as non-structural protein 2 (NS2). Subsequently, it was
noted that small amounts of NS2 protein were present in virions possibly interacting with
the viral matrix protein M1. NS2 was later implicated in mediating the export of vRNPs
from the host cell nucleus. This led to the proposal that the NS2 viral protein be
renamed as the nuclear export protein (NEP).Previous studies done by our group have
shown that several viral proteins are effectively SUMOylated. The NEP viral protein
exhibits characteristics that make it a likely SUMO target [6]. We will emphasize this
study on the potential effect(s) of SUMOylation on NEP.
In this project, we aim to explore the main interplay between the influenza A virus
and the cellular SUMOylation system in which our previous studies have indicated that
during influenza infection numerous viral proteins become SUMOylated. Therefore, to
better characterize the role played by the cellular SUMOylation system during influenza
infection, it is important to determine the specific effects exerted by SUMOylation on
each of the viral proteins targeted by this post-translational modification. The studies
presented here will focus on delineating the molecular effects mediated by the
SUMOylation of the viral protein NEP, which is an essential viral factor required for the
3

export of viral components from the cell nucleus. In addition, these studies will allow us
to determine whether NEP is a bona fide SUMO target during influenza infection to then
determine its effects during infection. Finally, the data generated will provide critical
insights on the post-translational regulation of NEP function and potentially lead to the
identification of a novel target for the development of an anti-influenza therapy.
Furthermore, these studies will expand our understanding of the interactions
established between viruses and the cellular SUMOylation system.
1.1 Influenza A virus
Influenza virus is a well characterized linear single-stranded, negative- sense
RNA virus with a total genome length of 10-15 Kb [5].This virus belongs to the
Orthomyxoviridae family which includes influenza virus types A, B, and C. Among the
most common Orthomyxoviridae viruses studied is the Influenza type A virus which is
mainly responsible for most flu pandemics affecting a widespread of avian and
mammalian species. Influenza type B is restricted to humans and influenza type C is
known to infect both humans and pigs.
The enveloped influenza A virus consists of eight gene segments, varying in
length between 890 and 2341 nucleotides. These eight RNA segments code for 10-11
different viral proteins. Most segments encode single viral proteins, with the exception of
segments 7 and 8, and in some strains segment 2 as well. Most DNA viruses replicate
in the nucleus using RNA polymerase II to create mRNA. On the other hand, RNA
viruses cannot use cellular Pol II, so they replicate in the cytoplasm. Influenza virus is
one of the few RNA viruses to replicate in the nucleus. This is due to the fact that the
influenza virus requires a functioning nucleus and the host cell enzymatic activities to
4

supplement viral enzymes during the expression of the viral genome, therefore leading
to an effective replication of the virus [7]. Each of the viral proteins encoded by the
influenza virus is described in Table 1.
Table 1. RNA segments and encoded proteins of the Influenza A virus:
Segment

1

Nucleotide

Amino acid

Protein

Protein

Length

Size

Encoded

Function

PB2

Protein basic 2; Binds to cap structure

2341

759

on cellular pre-mRNAs part of
transcriptase complex
2

2341

757

PB1

Protein Basic 1; RNA polymerase

PB1-N40

activity

for

transcription

and

replication

3

2233

716

PB1-F2

Induction of apoptosis

PA

Polymerase A; Part of transcription

PA-X

and replication complexes; posses
snipping (endonuclease) activity

4

1778

566

HA

Haemagglutinin;
glycoprotein;

major

surface

receptor-

binding;

mediates membrane fusion at low
pH; antigenic determinant
5

1565

498

NP

Nucleocapsid protein; binds and
encapsidates

vRNA;

control

functions in RNA synthesis
6

1413

454

NA

Neuraminidase;

major

surface

glycoprotein; receptor destruction;

5

dissociation of virus aggregates;
antigenic determinant
1027

7

252

Matrix

M1

protein;

interacts

with

envelope, nucleocapsids, and NEP
97

Integral

M2

membrane

protein;

ion

channel activity essential for virus
encoding and maturation
890

8

230

Nonstructural

NS1

regulation

protein

of

host

1;

down-

cell

mRNA

processing; sequesters dsRNA and
reduces interferon responses
121

Nuclear

NEP

export

protein;

directs

nuclear export viral nucleocapsids;
interacts

with

M1;

stimulates

synthesis of viral cRNP replication;
recruits F1Fo ATPase

.
The two large surface glycoproteins are the main antigenic determinants,
Haemagglutinin (HA) being the most abundant envelope protein covering 80%of the
surface and Neuraminidase (NA) which makes up nearly 17% of the viral envelope
proteins, both embedded in the lipid envelope [8].The Influenza A virus subtypes are
based on these two glycoproteins of the virus: the (H) hemagglutinin and (N)
neuraminidase. There are 16 H and 9 N subtypes. Influenza is a RNA virus with the
unique ability to replicate in the nucleus of its host cell. During infection the virion
attaches to sialic acid receptor on the surface of the cell via receptor binding site in the
6

glycoprotein HA to then enter the cell in an endosome through receptor mediated
endocytosis. The endosomal vesicle and the inside of the viral particle become highly
acidic due to the type III transmembrane protein M2, which serves as a proton-selective
ion channel in a viral envelope to allow the influx of the H+ ions. The acidity within the
viral particle triggers a non-reversible conformational change in HA, disruption of
protein-protein interactions between M1 and RNP causes an overall disassembly of the
core of the virus and release of viral RNA (vRNA) and core proteins to the cytoplasm of
the host cell. Since the transcription and replication occurs in the nucleus of the infected
cell, the vRNP must migrate to the nucleus. PB1, PB2, PA, and NP form the viral
polymerase complex (vRNP) which is translocated to the nucleus through Nuclear
Localization Signals (NLS) already present in all of the vRNP forming complex. These
viral proteins have the ability to bind to the cellular import machinery [8]. Once inside the
nucleus, the viral RNA-dependent RNA-polymerase (vRdRp) composed of PB1, PB2,
and PA initiate viral RNA synthesis to produce viral mRNA transcripts by a ‘cap
snatching’ mechanism [8,9,10].This is done by PB2 binding to the 5’ m7G caps of the
host mRNA which is then stolen by the N-terminus end of PA containing the
endonuclease activity to then be used as the primer for viral transcriptase [8,9]. Cellular
RNA polymerase II (Pol II) binds to DNA and start transcription. During transcription
initiation, phosphorylation of the serine 5 on the C-terminal repeat domain (CTD)
present on Pol II is then required to the activation of the cellular synthesis complex.
Then, M1 binds to a negative sense vRNPs through its C-terminal end and to
NEP through its N-terminal end masking the nuclear import signal (NLS) of the protein.
In turn, NEP binds to CRM1to export the vRNPs to the cytoplasm. After the vRNPs
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have been exported out of the nucleus, the virus has to form viral particles by using the
host’s plasma membrane to leave the cell. These viral proteins, which are later
transported to the apical plasma membrane, must contain the proteins within the viral
lipid bilayer; HA, NA, and M2 [11].Packaging of the 8 genomic segments has two model
hypotheses; random packaging and specific packaging model. The first one predicts
that the viral genomic segments are randomly packaged into virions; whereas the
specific packaging model predicts that there are specific signals within each of the viral
segments dictating which segments will be packed in the virion. Most importantly,
cleavage of sialic acid residues carried out by NA must occur before the viral particle
can leave the plasma membrane and infect neighboring cells.
The NS gene segment is the last and smallest gene segment of the influenza
virus encoding for two mRNA splice variants, NS1 and NEP. The non-structural protein
1 (NS1) is an important virulence factor expressed in high levels with a predominant
localization in the nucleus. This protein is known to exert multiple roles during influenza
infection, one of the most important functions is to antagonize host immune responses
(interferon responses) by antagonizing or limiting IFN-α/β production, inhibiting
apoptosis by PI3K activation, limiting the binding activity of PKR and OAS, preventing
maturation and migration of dendritic cells, and antagonizing putative host defense by
RNAi induction; all promoting viral pathogenicity. Several studies have indicated that the
NS1 viral protein is responsible for the virulence of highly pathogenic human influenza
viruses with the ability to cause viral pandemics [12].The second spliced product of the
NS gene segment is mainly known as a Nuclear Export Protein (NEP). Recently, this

8

protein has been associated to a couple of different roles during influenza infection as
described in the next section [13].

1.2 The role of the Nuclear Export Protein (NEP) in influenza A infection
Even though, the same segment (segment 8) encodes for the non-structural
protein NS1 and the
nuclear

export

protein, NEP, very
little is known about
this last one. NS1 is
a well characterized
protein

known

exert

to

multiple

functions

during

infection

to

antagonize
immune

host

responses

and to promote viral
pathogenicity.

NEP

is a less well characterized 14.5 kDa protein. Although NEP was initially designated as
anon-structural protein, it was later found in purified viral particles. Also, it has been
found in accumulation preferentially in the nuclei of infected eukaryotic cells. Previous
studies have suggested a role for NEP in regulating viral RNA replication providing a
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possible explanation to its nuclear accumulation [14, 15]. For this reason, NS2 was
renamed as the nuclear export protein (NEP). Exportins just like importins can directly
recognize nuclear export signals by binding to a second exportin molecule to interact
with the nuclear pore complex (NPC). Chromosome Region Maintenance Protein 1
(CRM1) is well known to mediate the export from the nucleus of many proteins, RNAs,
and ribonucleoproteins complexes carrying a nuclear export signal (NES) [16].In order
for CRM1 to leave the nucleus with the cargo, it needs to be associated to Ran and
these needs to be associated to GTP to form RanGTP. As soon as the
cargo/adaptor/CRM1/RanGTP leaves the nucleus; RanGAP stimulates the GTPase
activity of Ran, thus allowing it to cleave GTP into GDP. In the presence of GDP, the
ternary complex falls apart allowing the exportins and RanGDP to go back to the
nucleus, but the cargo remains in the cytoplasm[17].Previous studies have
demonstrated involvement of M1 in the nuclear export of vRNPs; these findings have
suggested that M1 is required for vRNPs to get exported from the nucleus [18].
The matrix 1 protein is a two domain protein with a nuclear localization signal
(NLS) on the N-terminal domain and affinity for RNPs on the C-terminal domain. In
addition, M1 does not have the required NES motif to export RNPs. However, this motif
is found in the N-terminal domain of NEP. It has been reported that the atomic structure
of the C-terminal half of NEP, has one face that is extremely acidic containing an
exposed tryptophan, W78, in the middle of glutamic acid side chains. These tryptophan
and the glutamic acid chains play a significant role in the binding to M1 as the binding
can be disassociated upon mutation of W78 to serine. Thus, the proposed model as
illustrated in Fig. 1 is as follows; in the nucleus, M1 binds to RNPs through its C-terminal
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domain, leaving its C-terminal domain with the NLS exposed so that this can associate
with the N-terminal domain of NEP. Then, NEP will bind to M1 through its C-terminal
domain leaving its N-terminal domain with the NES free for interactions with CRM1;
lastly binding to RanGTP is needed so the complex can be exported[19,20].
Recent studies have suggested additional roles for the Influenza NEP protein. As
mentioned above the main and most recognized role of this viral protein is to act as a
nuclear export protein, hence its name. In addition to the main role of NEP, this protein
has also been demonstrated to contribute to the viral budding process through
interaction with a cellular ATPase known as the F1Fo-ATPase. TheF1Fo ATPase is a
bifunctional enzyme complex that can be found mainly in the inner membrane of
mitochondria and plasma membrane of mammalian cells. This enzyme has the ability to
hydrolyze ATP as an AAA-type ATPase. As a bifunctional enzyme, it is composed of
two parts. The F1 portion consists of five subunits, and the Fo portions consist of nine
subunits. The ATPase activity of F1FoATPase is a critical factor for efficient influenza
virus budding, but further studies are needed to fully understand the role of ATPase
activity in virion budding [21].The role of NEP has not been identified yet, but it has
been demonstrated that NEP is associated to one subunit of the F1 portion at the
plasma membrane. Therefore, the interaction of NEP with the plasma membrane and
the F1β subunit suggested a role for this F1 subunit during the late step of the influenza
viral cycle [21]. Moreover, siRNA targeting F1β experiments revealed that M1 can
induce VLP production and that NEP enhances M1-induced virus-like particle (VLP)
production, which established a role for NEP in virion formation [21].
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Another recent role for NEP is the ability to regulate the accumulation of mRNA,
cRNA, and vRNA. Although the biochemical mechanism is not known yet, this ability
has been linked to a potential switch from viral transcription during the early stages of
viral replication to favor the production of genomic vRNPs [22].Interestingly, NEP plays
an important role in the adaptation of some avian H5N1 influenza viruses to replicate in
mammalian cells having a biological significance since most avian influenza viruses
cannot replicate efficiently in mammalian cells [23]. Moreover, it was demonstrated that
NEP has the ability to significantly inhibit reporter gene expression with concentrations
that could physiologically be reached by infected cells. Further experiments indicated
that high levels of NEP expression can inhibit the transcription as well as the replication
of all viral RNAs [24]. Overall, NEP seems to perform different biologically important
functions during influenza viral replication
Finally, NEP was reported to be SUMOylated in vivo when transiently expressed
in HEK293 cells. Out of the 11 proteins encoded by the influenza virus, M2 and NEP
exhibit some sequence variability among different viral strains. Even though NEP was
proven to be a potential target modified by the SUMOylation system, it is still
undetermined whether NEP would be SUMOylated under the normal levels of
expression and activity displayed by the cellular SUMOylation machinery.

1.3 SUMOylation: a post-translational conjugation system of the Small Ubiquitinlike MOdifier (SUMO)
Initial studies done at the SUMO-Influenza laboratory for cellular and molecular
virology, were based on the ability of the SUMO protein to regulate several viral
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proteins. Initial studies were done by in vitro SUMOylation reactions revealing 7 of the
viral proteins were SUMOylation with the exception of the two membrane viral proteins,
HA and NA, and PB1-F2 and M2. Moreover, in vitro and in vivo studies showed that
NS1 is a bona- fide SUMO target, making this the first report showing the relevance of
SUMOylation on the influenza virus [6].The cellular SUMOylation system is known to
affect a vast number of cellular proteins. As mentioned above, the SUMO protein has
the ability to regulate cellular localization, protein stability, half-life, and protein activity
[25].
As stated at the beginning of this project, SUMOylation is known to play a crucial
role in a variety of biological processes such as modifying a target protein by altering its
enzymatic activity, cellular localization, and serving as a docking site for other potential
interacting molecules. Some cellular processes regulated by SUMOylation include
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transcription, translation, protein degradation, and cell cycle regulation. The SUMO
protein is ~11kDa in size and resembles the 3-D structure of ubiquitin, while sharing
less than 20% amino acid sequence identity and 40% structure similarity to ubiquitin
[26, 27].Another difference between these two post-translational modification systems is
that the enzymes required for the SUMOylation cell cycle differ from the ones needed in
the ubiquitination cycle. SUMO pathway requires the E1 and E2 enzymes for
conjugation without the absolute need for the E3 ligase, while the ubiquitin pathway the
E3 ligase is necessary for conjugation [28].A unique element of the SUMO protein is
that it carries an unstructured stretch of 10-15 amino acids at the N-termini. There are
four different SUMO proteins, SUMO1, SUMO2, SUMO3 and the most recently
identified and least characterized; SUMO 4. SUMO 2 and 3 share 97% identity, so they
are frequently referred as SUMO2/3, whereas they only share 50% identity with
SUMO1, this being the most closely related homolog to ubiquitin. This post-translation
modification system involves a multistep process. SUMO is synthesized as a precursor
that is proteolytically cleaved near its C-terminal end by a SUMO protease (SENP) to
expose its internal di-glycine motif required for conjugation. Next, a mature form of
SUMO is triggered by the E1 activating enzyme in an energy consuming process. Then,
SUMO is transferred to the E2 conjugations enzyme known as Ubc9, which conjugates
it to a lysine residue of a target protein forming an isopeptide bond, which in some
occasions be facilitated by E3 ligases. After the conjugation, SUMO specific proteases
like SENP cleave the isopeptide bond between SUMO and its targeted protein, creating
a reversible and dynamic process as presented in Figure 2. Also, SUMO is conjugated
to the target protein via the isopeptide bond in the carboxyl group of its C-terminal
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domain glycine residue and the lysine residue in the target protein. For the most part,
the lysine residues are located within the SUMO consensus motif KXE,  being a
hydrophobic residue, K is the lysine residue, X stands for any amino acid, and finally E
is glutamic acid [29, 30, 31].
Furthermore, SUMO is emerging as a versatile modifier for a number of proteins
in different pathways with a diverse range of roles in many cellular processes. The
effects associated with SUMOylation are protein-specific, but the actual molecular
mechanisms by which these effects are achieved are still unknown. One of the proteins
regulated by the cellular SUMOylation system is the glucocorticoid receptor-interacting
protein1 (GRIP1) and the viral protein IE2-p86 where conjugation of SUMO enhances
their activity. Also, DNA binding activity of the heat shock factors HSF1 and HSF2 is
stimulated with SUMO conjugation. On the contrary, SUMOylation of several
transcription factors such as c-Jun, c-Myb, AP2, Sp3, and some nuclear receptors
demonstrated downregulation of their transcriptional activity. In addition, SUMO
conjugation is known to modify a large number of viral proteins by enhancing viral
propagation or exerting antiviral activities [32, 33].
1.4 SUMOylation and viruses
SUMOylation is an important protein function modulator. A number of viruses
interact with the cellular SUMOylation system either to secure the function of certain
viral proteins or by enhancing the system for viral propagation. In contrast, the host may
control the cellular system to prevent viral propagation. Although there are four isoforms
of the SUMOylation system, the SUMO1 protein has the ability to modify a broad range
of viral proteins from different viruses. Some of these viruses are the Human
15

Cytomegalovirus Immediate-early protein 1, HCMV-IE1, for which SUMO1 conjugation
is required for efficient viral replication by activating the IE1 protein. Another virus
modulated by the SUMO1 protein is the Bovine Papilloma virus E1 Protein; BPV-E1.
SUMO modification is necessary to trigger the helicase activity of the BPV-E1 protein,
thus allowing for intranuclear distribution and nuclear export [34].
On the other hand, there is evidence of SUMOylation exerting antiviral activities.
For example, the Gam protein produced by an avian adenovirus with the ability to
control the host’s SUMOylation system by promoting the ubiquitination of the SUMO E1
enzyme, thus leading to protein degradation [35]. Some viruses such as Epstein-Barr
virus and the Human Cytomegalovirus possess similar abilities to block the SUMO
modification of proteins, such as PML, thus leading to the disruption of essential steps
to induce viral infection [36, 37]. Also, the Ebola Zaire has the ability to hijack the host
SUMOylation system to suppress the innate immune response by SUMOylating IRF7[38].
Various siRNA screens in human lung epithelial (A549) cells and yeast two
hybrid screens identified SUMOylation as one of the host machineries required by the
influenza virus for effective viral replication [39, 40].More recent in vitro studies have
demonstrated interactions between the cellular SUMOylation system with seven out of
the eleven influenza viral proteins, predominantly with the non-structural protein NS1
[41]. Given that the influenza virus is an RNA virus not only with the ability to replicate in
the nucleus of its host cell, but with conserved consensus SUMOylation motifs among
different influenza virus strains, and the ability to interact with several viral proteins, it is
possible that SUMOylation is playing an important role during influenza virus infection.
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The interplay between influenza and the cellular SUMOylation system has gained
substantial relevance over the past years as it modulates a variety of cellular processes
affecting a number of essential cellular functions. For example, initial studies
demonstrated NS1A as a bona fide SUMO target, thus implying that the cellular
SUMOylation system may play important roles in during influenza infection. In addition
to NS1, several other influenza viral proteins were identified as bona fide SUMO targets
both in vitro and in vivo approaches, suggesting that there might be an active interplay
between the virus and the host cellular system. Moreover, the presence of two high
molecular weight bands, 70 and 52 kDa, are consistently present during viral infection
as well as a global increase in cellular SUMOylation. Interferon (IFN) is the main antiviral response mounted by the cell during viral infection. So, studies testing the effects
of IFN during viral infection demonstrated an increase on viral replication and an
increase on SUMOylation dependent on viral multiplication independently from IFNstimulation.
In order to enhance the SUMOylation of NS1, a novel technique was developed
referred to as the artificial SUMO ligase (ASL). This was created by a fusion of the Nterminal RNA binding domain (RBD) of the NS1 protein from PR8 with the SUMO
conjugating enzyme Ubc9. The interaction between the N-terminal region of NS1 and
the N-terminal region of NS1-Ubc9 positioned Ubc9 in relation to the N-terminal region
of NS1. The unstructured linker region of NS1 enabled the movement of Ubc9, creating
a fusion construct composed of amino acid residues 1-87 of NS1 and the full length
amino acid sequence of Ubc9. Consequently, Ubc9 was brought in close proximity to
the SUMOylation site of NS1, thus creating an increase in the SUMOylation of the
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protein. The endogenous SUMOylation of the protein was increased to a remarkable
level allowing for an extent functional analysis of the effects of SUMOylation on NS1
without increasing the global SUMOylation of the cell.
The development of the ASL leads to an extensive analysis on the effects of
SUMOylation on NS1. Extensive studies demonstrated that the SUMOylation of NS1
does not affect its stability or cellular localization of the protein. In addition, several
studies demonstrated that the abundance of SUMOylated NS1 is a major determinant of
NS1’s ability to neutralize IFN response. More importantly, our group has been the first
one to test the effect of the interplay between the SUMOylation system and the
Influenza virus in an animal model with the help of this novel tool [6, 28, 41].
1.5 Thesis goal
Our current research focus on the interactions between a post-translational
modification system known as SUMOylation and the influenza A virus. This Small
Ubiquitin-like Modifier (SUMO) has gained substantial relevance over the past years as
it modulates a variety of cellular processes. Previous SUMOylation prediction analyses
done using SUMOsp 2.0, revealed the presence of SUMO consensus motif(s) in most
influenza viral proteins. Given that influenza is among the very few RNA viruses to
replicate in the nucleus of host cells and that most of the viral proteins contain a
conserved SUMOylation consensus motif, we concluded a possible role of SUMOylation
during influenza infection. Several viral proteins, including NS1 and NEP, were shown to
be SUMOylated upon viral infection. Currently available data indicated that the cellular
SUMOylation system provides important functions for influenza upon infection, and
therefore may provide novel targets for the development of antiviral therapies. NS2/NEP
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has been well characterized as an adaptor allowing for the binding of viral RNPs and
nucleoporins and most likely for the transport of RNPs through the NPC into the
cytoplasm. Thus, for the purpose of this project, we hypothesized that
SUMOylation of Influenza NEP plays a crucial role in mediating the nuclear export
of the vRNPs in infected cells. Furthermore, we want to characterize the major role of
SUMOylation on this viral protein, with the ultimate goal to identify new therapeutic
approaches against influenza infections. To achieve this, we will pursue the following
specific aims:
Specific Aim 1: Test whether NEP is a bona fide or true SUMO target during
influenza viral infection.
Specific Aim 2: Characterize specific SUMOylation site(s) in NEP.
Specific Aim 3: Characterize the role(s) exerted by SUMOylation on NEP upon
Influenza viral infection.
Our preliminary SUMOsp 2.0 analysis revealed the presence of conserved
SUMO motifs (ΨKXD/E) on most influenza viral proteins including NEP. This protein
contains a total of seven lysine residues with only one, K72, serving as a potential
SUMO target. All influenza viral proteins were tested using an in vitro transcriptiontranslation approach resulting in seven efficiently SUMOylated viral proteins. Additional
immunoblots were performed using the total cell extracts of transfected mammalian
cells revealing the presence of higher molecular weight form of NEP. The new form
appeared to be a SUMOylated form of NEP due to the apparent high molecular weight
of approximately 20 kDa larger than the unmodified wild-type protein. This change in
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size corresponds to the molecular weight of His-S-SUMO1. Secondly, the higher
molecular form of the protein was not visible in the presence of SENP1. As mentioned
above, segment 8 codes for two viral proteins, NS1 and NEP. Extensive data has
demonstrated that NS1A is the best SUMOylated protein on the influenza A virus;
therefore it is easy to assume that NEP might also be modified by this cellular system.
Due to these intriguing findings, it will be of high relevance to further characterize the
SUMOylation of all viral proteins identified as potential SUMO targets. This study will
allow us to identify the ground breaking role(s) of SUMOylation on NEP.
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Chapter 2: Identification of the Nuclear Export Protein (NEP) as a target of the
cellular SUMOylation system.
The Influenza virus is composed of 8 gene segments which can code for 10-12
viral proteins. Our previous studies have demonstrated that seven (PB2, PB1, PA, HA,
NP, NA, M1, and NEP) out of the 11 viral proteins are effectively SUMOylated in vitro
and at least five are SUMOylated in vivo. The Nuclear Export Protein has been shown
as a possible candidate for interacting with the cellular SUMOylation system. Previous
data provided by former graduate students in Dr. Rosas-Acosta’s lab, has shown strong
interactions between the cellular SUMOylation system and the influenza viral protein
NEP through mass spectrometry and in vivo experiments. Despite these experiments,
there is no direct data indicating that NEP is regulated by this cellular system and how.
In this specific aim, we demonstrated the cellular SUMOylation system regulates the
influenza viral protein NEP.
2.1 Materials and Methods
2.1.1 Immunoprecipitation

A549 cells were infected with WSN/T7T7NS1K701K219A~NS2 and MOCK at an
MOI of 10. Then, cells were collected 12 h.p.i (hours post-infection) with SDS collecting
buffer. Samples were then IPed either with anti-SUMO1 or anti-T7 and blotted against
anti-NS2 and anti-SUMO, respectively.
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2.1.2 Transduction and infection

To test the SUMOylation of NEP by transduction followed by infection, A549 cells
were transduced with the Dual-SUMO1 (T95RQ94P) adenovirus at three different MOIs
of 50,100 and 200. This plasmid up-regulates cellular SUMOylation due to the Q94P
mutation preventing SUMO deconjugation from its target protein. The T95R mutation
introduces a trypsin cleavage upstream the di-glycine motif of SUMO creating a
signature tag and allowing for easy detection on any target protein containing a
SUMOylation site. In order to test the effects of SUMOylation on NEP, we needed to
separate NEP from NS1 and test them individually. The double mutant construct,
WSN/T7T7[NS1K70AK219A~NS2], was initially created to test the effects of
SUMOylation solely on NS1.Introduction of the K219A mutation, one of the main
SUMO sites on NS1, into NS1 created a lethal N62H mutation on NEP. Therefore, we
created a construct that could test the SUMOylation of NS1 in the absence of changes
in the primary sequence of NEP by separating the open reading frame (ORF) for NS1
from NEP, while allowing NEP to still be produced as a splicing product. The splicing
acceptor site on NS1 was inactivated by site-directed mutagenesis, then placing a copy
of the second exon for NEP with a functional splicing acceptor site, downstream from
the stop codon for NS1.Conclusively with this construct, cells were incubated for24
h.p.t. and infected with the double mutant influenza virus, and incubated for an
additional 24 hours. Cells were transduced only, infected only, or transduced and
infected. The cells were collected using 4X boiling sample buffer and the effects were
evaluated by quantitative IR Western Blot analysis.
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2.1.3 Transfection

To confirm the site of the SUMOylation on NEP, a point mutation bearing K to A
substitution of the residue previously indicated at position 72 were generated. To this
end, we generated the mutation using a previous plasmid with the NEP ORF shifted
from the NS1K70AK219A~NS2 construct (from here on referred to as NS2[SUMO]). To
analyze the effects of the point mutation on NS1K70AK219A~NS2K72A (from here on
referred to as NS2[non-SUMO]), HEK293FT cells were be transiently transfected with
the shifted NS2 constructs along with RNA-dependent RNA-polymerase, which include
PA, PB1, PB2, and NP plasmids all driven by a Pol1 promoter only. At 24 hours posttransfection, the cells was collected using 4X boiling sample buffer and the
SUMOylatability of the mutant NS1DM~NS2K72A was evaluated by quantitative IR
Western Blot analysis.

2.2 Results
2.2.1 Purification of NEP by immunoprecipitation:

The molecular weight of NEP is approximately 14.5Kd. The addition of a T7 tag
on our construct (molecular weight of 11kD) which form of the SUMO protein is
~23.5kD, which suggests a possible SUMOylation event on this protein when cells are
transfected with the SUMO-deficient form of NS1. Interestingly, there is no previous
record from other groups studying the interactions between NEP and the cellular
SUMOylation system.
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In order to confirm the identity of the shifted band obtained in co-transfections with the
SUMO-deficient plasmid, we performed several co-IPs. Immunoprecipitations were
used to isolate and concentrate the purified form of NEP. Therefore, we infected MDCK
and A549 cells with a NS1-SUMO deficient influenza virus and a wild type shifted
influenza virus. Additional controls
consisted on MOCK infected and
rabbit serum used for direct binding
of the G beads. Despite the effort,
we were unable to succeed on this
approach. A number of experiments
were performed testing for different
conditions such as, different lysis
buffers, hours post-infections, MOI’s,
higher density of cells, cell type, and
transfection followed by infection.
Unfortunately, we were never able to
detect the presence of a higher
molecular weight form of the protein.
We have only being able to detect
heavy and light chains on both IPed
samples in most the experiments. In addition, supernatants were collected for every
step of the protocol (e.g. TCEs before adding antibodies, after G bead pre-absorption,
etc.) and analyzed by Western Blot,

presenting a very faint band distinctive of
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endogenous NEP. All attempts to this approach were inconclusive and the purification
of the SUMOylated form of NEP remains elusive.

2.2.2 Testing the SUMOylation of NEP by Dual- SUMO1 transduction and infection with
dual mutant Influenza virus

Previous experiments confirmed that co-transfection with lysine to alanine
mutations at positions 70 and 219, identified as the two main SUMO sites on NS1,
referred as the double mutant (DM) construct, revealed the appearance of a new band
at ~38kD which coincides with the SUMOylated form of NEP. A straight-forward
approach to determine whether NEP was modified by the cellular SUMOylation system
was to add a His-tag to create a shift on the protein band of interest. The additional shift
on the potential SUMOylated NEP band served as a confirmation of the SUMOylated
form of the protein. We determined whether NEP was SUMOylated during infection with
a DM influenza virus followed by overexpression of the dual-SUMO1 adenovirus
transduction on A549 cells. This approach produced an additional shift of approximately
4kDa caused by the His-tag present in the dual-SUMO1 adenovirus, thus allowing
further confirmation on the SUMOylated form of NEP.
The results presented the appearance of the ~38kD protein band in samples that
were infected with the DM influenza virus. Intriguingly, as shown in Fig. 4 (lane 5), there
is a new band at ~75kD present only when cells are transduced at an MOI of 100
followed by influenza infection with the DM virus. The identity of the band is still
unknown. We discarded the possibility of a shifted version of a SUMOylated NEP,
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because the shift is more than 30kD higher than the expected shift of a SUMOylated
form of NEP with the His-tag. Based on the data collected, we were able to reproduce
the same band at ~38kD from transfection experiments when cells are transduced with
a dual-SUMO1 adenovirus followed by infection with the DM influenza virus. Another
possibility might be an alternative spliced form of the NS primary transcript that results
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in a protein that shares NEP end, but with an extra sequence upstream of the 2nd exon
of NEP.

2.2.3 Mapping the SUMOylation site(s) of the Nuclear Export Protein

The development of a non-SUMOylatable form of NEP is essential to assess the
effects exerted by SUMOylation on this particular protein allowing us to evaluate the
effects caused exclusively by the cellular SUMOylation system. Therefore, it is crucial to
first assess possible SUMO consensus motifs (KXE) by identifying lysine residue(s)
responsible for the interaction between SUMO and NEP.
The tentative SUMOylation site(s) on NEP was predicted using the SUMOsp 2.0
software. Next, the predicted lysine residue(s) was mutated to an alanine residue using
a site-directed mutagenesis approach. Finally, the site of SUMOylation was confirmed
by evaluating the SUMOylatability of the mutant protein by transient transfections in
HEK293FT cells.
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Following the procedures described above for IR Western Blot analysis, we
identified what seems to be the main SUMOylation site on NEP. As shown on Fig. 6, the
appearance of a new higher molecular weight form of NEP at approximately 38kD is
present with the addition of the NS2[non-SUMO]. The expression of the possible
SUMOylated form of NEP was substantially decreased with the addition of the K72A
mutant construct compared to the levels of SUMOylation observed with NS1DM~NS2,
thus indicating that the mutation substantially decreases the SUMOylation of NEP.
Western Blot analysis with anti-NS1 antibody reveals the presence of the NS1 viral
protein in samples containing the NS2[non-SUMO] and NS2[SUMO] constructs,
indicating that the NS1 sequence was not altered in the making of the constructs. In
addition, the membrane was incubated with anti- GAPDH to serve as a loading control
to indicate similar levels of protein loaded for all the different samples. An additional
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experiment was done using EGFP as a transfection control. In Fig.7, the intensity of the
EGFP is similar in all the samples co-transfected with EGFP, thus indicating that the
decrease in the intensity of the NS2[SUMO] and the NS2[non-SUMO] is not due to a
decrease in transfection efficiency. The data presented here identifies a potential SUMO
site on NEP.
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2.3 Discussion

Studies looking at the interactions of the Influenza A virus and the cellular
SUMOylation system have shown the Non-structural protein, NS1, as a bona fide
SUMO target. Extensive analysis have been focused on the effects of SUMOylation on
NS1 only. Previous data shown described by Pal et al. 2011, indicated that at least 7
out of the 11 viral proteins of the influenza virus can interact with the SUMO protein
during in vitro analysis [6]. The nuclear export protein is one of the possible SUMO
targets described in the analysis. The purpose of these studies is to determine whether
NEP is a true SUMO target. Unfortunately, we were not able to purify a SUMOylated
form of NEP nor detect a high molecular weight band of the protein during
immunoprecipitations. Furthermore, we were unable to detect a shift in the high
molecular weight form of NEP even with the addition of a His-tag during transduction.
Despite our efforts to test whether NEP is a true SUMO target, we were able to map its
main and possible only SUMOylation site. After SUMOplot analysis, we mutate the
lysine residue at position 72 of the protein to an alanine residue in order to prevent the
SUMOylation of NEP. As seen in Fig. 6, the appearance of a high molecular weight
band is present when cells are transfected using a non-SUMOylated form of NS1
shifted construct. The same band is greatly diminish in the presence of the mutation,
K72A, on NEP indicating that this is in fact lysine residue responsible for the interaction
between SUMO and NEP. After extensive analysis NEP amino acid sequences, we are
certain that the effects seen during the production of a higher molecular weight band are
not due to an improper shift on the ORF of NS1 or NEP. Furthermore, the presence of
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NS1 eliminated the possibility that the high molecular weight band is a fusion of NS1
and NEP.
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Chapter 3: Characterization of the specific SUMOylation site(s) on the Nuclear
Export Protein (NEP) and its effects exerted upon Influenza infection
The Influenza virus is unique among RNA viruses by replicating in the nucleus
where SUMOylation appears to be most predominant. Among those SUMOylated
proteins NEP was shown to be effectively SUMOylated in vivo when transiently overexpressed in mammalian cells.

Along with these facts, most of the influenza viral

proteins bear one or more predicted SUMO consensus motif(s), indicating that the
influenza viral proteins may be targeted by the cellular SUMOylation system. In this aim
we will seek to identify the SUMO target(s) present on NEP. To achieve this goal, we
developed a lysine to alanine mutant at the one possible SUMO motif on NEP. Previous
studies identified two main SUMO sites on the non-structural protein NS1A. Lysine
residue 219 acts as the primary SUMO site followed by lysine residue 70. Lysine to
alanine mutations at the two main SUMO sites on NS1 decreased the levels of
SUMOylated NS1 even on the presence of an artificial SUMO ligase (ASL).
3.1 Materials and Methods
3.1.1 Transfection

To determine transfection efficiencies of the NS2[SUMO] construct,HEK293FT
cells were transiently transfected with the shifted NEP constructs along with RNAdependent RNA-polymerase, which include PA, PB1, PB2, and NP plasmids all driven
by a Pol1 promoter only. EGFP was added to the co-transfection to serve as a control
for transfection efficiencies. At 24 hours post- transfection, the cells was collected using
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4X boiling sample buffer and the transfection efficiencies of the NS2[SUMO] plasmid
were evaluated by quantitative IR Western Blot analysis.

3.1.2 Stability assay using cyclohexamide
To assess whether SUMOylation is having an effect on the stability of NEP,
HEK293A cells were co-transfected with (+) or without (-) NS2[non-SUMO] and
NS2[SUMO] constructs. At 24 post-transfection, cyclohexamide, CHX, was added to the
cells to a final concentration of 4mM and incubated for an additional 4, 6, 12, and 24
hours post treatment. Cells were collected using 4X boiling sample buffer and the
stability of SUMOylated NEP was evaluated by quantitative IR Western Blot analysis.
Successive

rounds

of

immunoblotting

were

done

using

anti-

NS2 PAb, anti-NS1 MAb, as primary antibodies. Highly cross-absorbed secondary
antibodies were used. Membranes were analyzed using the Odyssey CLx.

3.2 Results
3.2.1 Confirmation of transfection efficiencies of the NS2[SUMO] plasmid

Exact transfection of a plasmid is almost impossible to achieve. The addition of a
plasmid to different wells of cells can create variations on the amount of plasmid added
due to pipetting errors and cell density. Therefore, we decided to co-transfect the cells
with EGFP as a transfection control and test the transfection efficiency throughout the
experiment. This will allowed us to determine whether the effects previously seen in
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Fig.7

were

due

to

transfection
efficiencies or a real
decrease of NEP when
cells were transfected
with

NS2[SUMO]

plasmid.
As

stated

above, the efficiency
and

volume

transfected

of

a

plasmid

can differ from well to
well.

Therefore,

we

decided to determine whether the intensity of the ~38kD band decreased in cells cotransfected with the NS2[SUMO] plasmid were due to actual effects caused by the NEP
K72A mutation or to transfection efficiencies. The data obtained revealed that the
decrease in the band intensity of the NS2[SUMO] transfected cells was not due to
problems or variability on the transfection technique. The expression of EGFP was
approximately the same throughout the samples. Conclusively, the lysine to alanine
mutation at residue 72 on the NEP Influenza viral protein is causing an effect by
decreasing the expression of the ~38kD protein band. This leads to conclude that the
K72A mutation could be the main SUMO site for NEP.
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3.2.2 Testing the stability of the NS2[SUMO] using CHX treatment

To date, there is no evidence of any modification mediated by SUMOylation on
the NEP viral protein. Previous studies have demonstrated that SUMOylation does not
affect either the cellular localization or the stability/turnover of the PR8 NS1 [39].Since
the NEP mRNA derived from the NS gene segment is a spliced product of the NS1
mRNA, we considered essential to determine whether SUMOylation affects the stability
of this viral protein.
Under the conditions described above, both NS2[SUMO] and NS2[non-SUMO]
accumulated to similar levels in the cells and appeared stable, not displaying significant
decrease in cellular levels in any of the samples analyzed. Furthermore, the enhance
SUMOylation observed upon the addition of the NS2[SUMO] construct did not seem to
affect the stability of the protein, as similar profiles were observed with the addition of
the NS2[non-SUMO] construct. Quantitative analysis performed by the Odyssey CLx
infrared imaging system demonstrated little fluctuation in the cellular quantities of NEP
throughout the experiment.
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3.3 Discussion:
As described above, a mutation at lysine residue 72 decreases the SUMOylation
of NEP. We were able to prove that the high molecular weight band of NEP in the
presence of the non-SUMOylated form of NS1 shifted construct is not an artifact of
transfection efficiencies. Also, we were able to prove that the SUMOylation of NEP does
not have an effect on the stability of the viral protein.
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Chapter 4: Characterized the role(s) exerted by SUMOylation on NEP upon
Influenza viral infection
Previous studies done by our group presented NEP as a potential SUMO target.
Based on preliminary data from specific aim 2, SUMOylation is binding to NEP through
residue K72. Therefore, we will characterize the potential role of SUMOylation on the
already known functions of the NEP viral protein as a nuclear export transporter. NEP is
the second smallest viral protein in the Influenza A virus. In addition to the ability of NEP
to act as a nuclear export of vRNPs, two more roles have been linked to this viral
protein during influenza virus replication, i) the ability to contribute to viral budding
through the interaction with a cellular ATPase referred as F1F0-ATPase, ii) the
capability to regulate the accumulation of influenza virus mRNA, cRNA, and vRNA. As
SUMOylation is known to affect the function of a number of proteins from a variety of
viruses, the study of the role of SUMOylation on this nuclear export protein is likely to
provide exciting insights to the development of novel anti-influenza therapies.

4.1 Materials and Methods
4.1.1 Confocal Microscopy

To monitor the localization of wild type NS2 and the possible SUMOylated form
of NEP, MDCK cells will be seeded and infected for 6, 12, 18, and 24 hours with either
WSN/T7T7NS1~NS2 and WSN/T7T7NS1K70AK219A~NS2 influenza virus at an MOI of
1. Cells were then fixed with 100ul of 4% paraformaldehyde and incubated for at least
30 min., the cells were fixed and analyzed by immunofluorescence using DAPI as a
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DNA dye and anti-NS2 PAb as primary antibodies. We used highly cross- abundant
anti-mouse and anti-rabbit secondary antibodies.

4.2 Results
4.2.1 Characterization of the potential effect of SUMOylation on the localization of the
viral protein NEP

SUMOylation is known to modify several cellular processes, such as
transcription regulation of transcriptional factors, apoptosis, protein stability, sub-cellular
localization, and many more. In order to determine if SUMOylation plays a role in the
sub-cellular localization of NEP, we will evaluate the effect of SUMOylation on the
localization of NEP using a wild type shifted NS2 influenza virus and the double mutant
shifted NS2 influenza virus, NS1~NS2 and NS1K70AK219A~NS2 respectively. Both
viruses were done by inactivating the splicing the acceptor sites located on NS1 and
placing a copy of the second exon with a functional splicing acceptor site for NEP,
downstream from the stop codon for NS1. The NS1~NS2 is the wild-type form (no
mutations) of the virus and the NS1K70AK219A~NS2 virus contains K to A mutations at
positions 70 and 219. To achieve this goal, we will determine if there is any alteration in
the localization of the double mutant virus, which exhibits the presence of a higher
molecular weight band in the experiments described above and the wild type shifted
virus.
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4.3 Discussion

As shown in Fig.9, there was a significant change observed in the cellular
localization of cells infected with the wild type NEP and the double mutant shifted NEP.
As evidenced in the merge images, localization of NEP infected with the DM virus was
altered compared to the localization seen in the wild type. In cells infected with the wild
type virus, the localization was mainly nuclear, whereas in the cells infected with the DM
virus, the localization was mainly homogenously distributed between the nucleus and
the cytoplasm. These data confirmed that SUMOylation may be playing a main role
affecting the subcellular localization in NEP.
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Chapter 5: Summary and Discussion
At the moment, the most effective treatment against influenza virus is
vaccination. However, there are a number of caveats with vaccination. First, effective
vaccination requires antigenic match between the current viral type being transmitted
among the population and the viral strain used during the development of vaccines or
the strain present in current vaccines. Second, the high mutation rate of the virus due to
the error prone of the RdRp introduces a high variation of the antigenic structure of the
virus diminishing the effectiveness of current vaccines. The annual vaccination is
targeted to the viral strains that closely resemble the changes occurring in the prevalent
viral population. Generally, strain selection and vaccine production are time consuming
procedures; vaccine development against a novel pandemic can easily take up to 6
months, thus making vaccination an inappropriate preventive weapon for viral infections
during a viral spread.

Currently, there are two available anti-influenza drugs that have been proven to
be helpful at preventing transmission of influenza. The first one is known as
Adamantanes which target the viral M2 ion channel; and Neuraminidase inhibitors
known to target the neuraminidase viral protein. There are two Adamantanes,
Amantadine and Rimantadine, which are chemically derived from Adamantanes, and
act by blocking the ion channel from the M2 transmembrane viral protein, therefore the
acidification of the viral particle is prevented as well as the release into the cytoplasm of
the host cell. Also, there are two available neuraminidase inhibitor drugs, Oseltamivir
and Zanamivir, clinically referred as Tamiflu and Relenza correspondingly. These drugs
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block viral release at the plasma membrane, thus preventing the spread into
surrounding cells [45].
The resistance of Adamantanes was noted during its early development, but was
not recognized as a real issue until the wide resistance was noticed, leading to the
discontinuation of the drug two years later. Consequently, all circulating influenza
strains are resistant to Adamantanes and the drug is no longer in use [46].
On the other hand, Oseltamivir was considered to be much more difficult to
develop resistance because the mutations involved in providing the resistance to the
drug were thought to reduce viral fitness and viral transmission [47]. However,
resistance has been reported on the 2009 H1N1 influenza strain, thus making
Oseltamivir likely to become resistant to circulating and future influenza viral strains.
[48].
Evidently, there is an urgent need for an alternative weapon to combat future
influenza viral pandemics. Current anti viral weapons such as vaccination and viral
drugs are unlikely to play a major role in the control of highly pathogenic strains during a
pandemic. The high mutation rate of the virus targeting viral components makes it
difficult to develop a universal drug or vaccine against any strain of the virus. Available
viral weapons have been proven to minimize the effect of seasonal influenza
pandemics, but are very unlikely to eradicate the infectious disease.
One alternative to combat the virus is to target cellular factors necessary for the
viral growth and multiplication of the virus, which are less prone to be affected by the
emergence of resistant viral strains. Fortunately, targeting cellular systems of the virus
will work independently of the strains and antigenic properties of the virus. This
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approach will be of great advantage considering the broad array of subtypes of the
virus. The only main drawback is that drugs targeting host cellular factors might be toxic
to the host and could exert secondary effects. A wide variety of different antiviral
approaches have been studied, leading to the targeting of cellular factors as the most
promising approach [49].
Our lab has been the first group to identify several influenza viral proteins
efficiently SUMOylated in vitro [41]. There is a substantial amount of knowledge on the
basic functionality of the non-structural protein, NS1. Despite this, no one has looked at
the potential interactions between the cellular system and NEP. In this project, a
SUMOplot analysis identified the presence of a highly conserved SUMO motif at K72.
As shown in the mutagenesis study, the presence of a high molecular weight, HMW,
form of NEP was evident in cells transfected with a NS1DM~NS2 construct, the
decrease of this HMW band was measured in samples transfected with the predicted
K72 residue mutated in the shifted NS2 portion of the NS1DM~NS2 construct. These
results demonstrated an interaction between the cellular SUMOylation system and the
viral NEP. Considering the small size of the protein, K72 is likely to be the only SUMO
motif present in NEP. Interestingly, the presence of the HMW form of NEP was not
present in cells transfected with a non-shifted construct. This suggests a possible
competitive biological mechanism between NS1 and NEP for SUMOylation.
Although the biological implications of SUMOylation for NEP still remain
unknown, we were able to identify several roles of the protein upon SUMOylation. First,
we were able to map what seems as the main SUMO site on NEP. These results were
replicated many times throughout the completion of this project. Second, our group
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demonstrated that SUMOylation does not affect the stability of PR8 NS1, so we tested
for the stability of SUMOylated NEP with similar results. Third, the cellular localization of
NEP is affected by the cellular SUMOylation system. The cellular localization of NEP
was mainly nuclear in cells infected with a wild-type virus, whereas in the cells infected
with the DM virus, the localization was mainly homogenously distributed between the
nucleus and the cytoplasm. These data confirmed that SUMOylation is playing a role
affecting the sub-cellular localization in NEP. Collectively, this study extended the
knowledge of the interplay between the influenza virus and the cellular SUMOylation
system, reporting NEP as a SUMO target and recognizing possible crucial roles of the
protein upon SUMOylation for the first time.

5.1 Future Directions:

The influenza virus remains as one of the deadliest diseases in history. The
increasing resistance of the current viral weapons creates likelihood for a viral outbreak.
Analyzing how the influenza virus interacts with the SUMOylation system may provide
new tools to develop a broad spectrum antiviral therapy independent of viral strain. In
this study, NEP was identified as a new SUMO target. It will be intriguing to analyze the
possible effects of the cellular system on the influenza NEP. In order to further
understand the role of SUMOylated NEP, a virus coding for NS1DM~NS2K72A will be
of great relevance to test the effects of cellular localization of NEP during infection with
a non-SUMOylatable NEP. More importantly, studies need to fully demonstrate NEP as
a bona fide SUMO target. Tough the precise role of SUMOylation on NEP is still
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unknown; the accumulating evidence will provide insights on the biology of the virus and
will further support the relevance of exploring SUMOylation as a potential therapeutic
agent against the influenza virus.
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Appendix A
SUMOylation does not affect either the cellular localization or the
stability/turnover of PR8 NS1.
Importantly, for certain substrates, SUMOylation with SUMO2/3 is known to
trigger the formation of long poly-SUMO chains that are recognized by ubiquitin ligases
and lead to the poly-ubiquitinylation of the SUMOylated substrate, which in turns leads
to their proteasomal degradation [50]. Data obtained during the execution of these
experiments revealed the formation of poly- SUMOylated NS1 in the presence of wtASL and mut-ASL. As these occurred in the absence of exogenously added SUMO, the
data indicated that NS1 was likely to be preferentially modified by SUMO2/3 in vivo and
therefore suggested a potential role for SUMOylation in regulating the stability of NS1.
Furthermore, a previous report indicated that SUMOylation affects the function of
the NS1 protein of a highly pathogenic avian influenza A virus strain by increasing its
half-life [51]. Therefore, we considered it essential to determine whether SUMOylation
affected PR8 NS1’s stability. To measure the effect of SUMOylation on PR8 NS1’s
stability, we co-transfected HEK293FT cells with expression constructs for wt NS1 and
NS1K70AK219A. To potentiate the effects mediated by SUMOylation, some cells were
also transfected with mut-ASL.
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Additionally, the cells were also co-transfected with C/EBP-β1, a transcriptional
regulator that exhibits an intermediate half-life in the cell. Next, at 24 h post transfection,
the cells were treated with cycloheximide, an inhibitor of protein synthesis, and samples
were collected at 4-h intervals after cycloheximide treatment. Under these experimental
conditions, both wt NS1 and NS1K70AK219A accumulated to similar levels in the cell
and appeared very stable, not displaying any significant decrease in cellular levels
during the time span analyzed (Fig. 11A, compare, for example, lanes 6 and 10 to lanes
16 and 20). Furthermore, the enhanced SUMOylation observed upon addition of mutASL did not seem to affect the stability of NS1, as very similar profiles were observed in
the presence and absence of mut-ASL (Fig. 11A, compare lanes 11 and 15 to lanes 21
47

and 25). Quantitative analyses performed by using an Odyssey CLx infrared imaging
system in combination with IRDye-conjugated secondary antibodies demonstrated little
fluctuation in the cellular quantities of NS1 throughout the experiment (Fig. 11B). Similar
analyses performed with the co-expressed protein C/EBP-β1 showed substantial
changes in the cellular concentration of C/EBP-β1 throughout the
time frame analyzed, therefore demonstrating that the cycloheximide treatment had
been effective (Fig. 11B). Altogether, our stability analysis performed by using
cycloheximide treatment, indicated that the non-SUMOylatable form of PR8 NS1
exhibited stability similar to that of its wt form and that co-expression of mut-ASL did not
affect their stability, therefore strongly indicating that SUMOylation does not affect the
stability of PR8 NS1.
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